GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axcella Health Inc (OTCPK:AXLA) » Definitions » 3-Year FCF Growth Rate

Axcella Health (Axcella Health) 3-Year FCF Growth Rate : 25.20% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Axcella Health 3-Year FCF Growth Rate?

Axcella Health's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-1.24.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 25.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Axcella Health was 25.20% per year. The lowest was 2.30% per year. And the median was 9.00% per year.


Competitive Comparison of Axcella Health's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Axcella Health's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axcella Health's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axcella Health's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Axcella Health's 3-Year FCF Growth Rate falls into.



Axcella Health 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Axcella Health  (OTCPK:AXLA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Axcella Health 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Axcella Health's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Axcella Health (Axcella Health) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 1270, Littleton, MA, USA, 01460
Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.
Executives
Paul Fehlner officer: Senior Vice President, CIPO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
William Hinshaw director, officer: President and CEO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
L.p. Fpa, 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Fpa General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Societe Des Produits Nestle S.a. 10 percent owner AVENUE NESTLE 55, VEVEY V8 CH-1800
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Torben Straight Nissen director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Michael Rosenblatt director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martin Hendrix director C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Robert Crane officer: Chief Financial Officer 101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109